SMSPHARMA.BOSMSPHARMA.BOBSE
Loading
EBITDA Over TimeExpanding
Percentile Rank100
3Y CAGR+44.6%
5Y CAGR+7.6%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

3Y CAGR
+44.6%/yr
vs -10.7%/yr prior
5Y CAGR
+7.6%/yr
Recent acceleration
Acceleration
+55.3pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
1.4x
Solid growth
Streak
3 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$1.79B+23.5%
2025$1.45B+23.6%
2024$1.18B+97.9%
2023$593.89M-50.3%
2022$1.20B-4.0%
2021$1.25B+46.5%
2020$850.33M-9.1%
2019$935.01M-2.3%
2018$957.28M+25.6%
2017$762.46M-